Company Profile
Adagene Stock Price, News & Analysis
- Ticker:
- ADAG
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- China and listed in the U
Stock performance
4.14 USD (-2.13%)
Close
Last updated: August 6, 2026
224M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ADAG closed down 2.13% at $4.14. No new same-company headline was identified in the current news window.
Company overview
Business overview
Adagene is a biotechnology company focused on next-generation antibody engineering and cancer immunotherapy. Its story is built around precision antibody design and the effort to create differentiated oncology medicines.
Geographic Base and Sector Classification
Adagene is headquartered in China and listed in the U.S. market. It sits in oncology biotechnology with a platform-engineering identity.
Business Model Characteristics
The company depends on translational validation, clinical data, and the ability to turn antibody engineering into clinical value. Investors watch proof-of-concept, partnerships, and capital runway.
Position Within the Biotechnology Landscape
Adagene occupies a specialized antibody-engineering niche within biotech. It is catalyst-sensitive because the platform still needs to prove broad therapeutic differentiation.
Future catalysts
Adagene’s catalysts are its immune-modulating antibody platform and any clinical or partnership update that shows the technology can still differentiate. The company still needs stronger human proof.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Adagene (ADAG)?
Adagene (ADAG) most recently closed at 4.14 USD, a -2.13% move versus the previous session.
What is the market cap of Adagene (ADAG)?
Adagene currently has a market capitalization of 224M USD on BioPharmSignal.
What does Adagene do?
Adagene is a biotechnology company focused on next-generation antibody engineering and cancer immunotherapy. Its story is built around precision antibody design and the effort to create differentiated oncology medicines.
On which exchange is ADAG stock listed?
Adagene (ADAG) is associated with NASDAQ, China and listed in the U, Biopharma.
What is Adagene?
Adagene’s catalysts are its immune-modulating antibody platform and any clinical or partnership update that shows the technology can still differentiate.
Which conditions is Adagene targeting with Adagene?
Adagene is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Adagene describe recent progress with Adagene?
Adagene’s catalysts are its immune-modulating antibody platform and any clinical or partnership update that shows the technology can still differentiate.
What future catalysts are investors watching for Adagene?
Adagene’s catalysts are its immune-modulating antibody platform and any clinical or partnership update that shows the technology can still differentiate. The company still needs stronger human proof.